H. Lundbeck, Interim report for the third quarter of 2006

The Supervisory Board of H. Lundbeck A/S today approved the Group s interim report for the third quarter of 2006. Underlying growth in Lundbeck s business outside the USA is satisfactory, but as in the two previous quarters, the consolidated financial performance is adversely affected by Forest Laboratories, Inc. s reduction of in-house escitalopram inventories in 2006.